Skip to main content

Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
Quick Connect

White Paper

Apalutamide API – an attractive NCE-1 opportunity for generic pharma companies

Prostate cancer accounts for 7.3% of all incident cases of cancer globally, as per estimates released by Globocan 2020. The 5-year prevalence of prostate cancer is estimated at ~ 5 million worldwide, making it the second most common cancer among men.

Apalutamide is an oral second-generation, nonsteroidal androgen receptor inhibitor and became the first FDA-approved drug for non-metastatic castration-resistant prostate cancer patients. It received additional approval in 2019 for metastatic hormone-sensitive prostate cancer and is in phase 3 trials for metastatic hormone-refractory prostate cancer.

Our API allows formulators to choose an IP-compliant market entry that meets the regulatory requirements. The key aspects of our offering are: 

To continue reading our whitepaper, please fill in the contact form below

Explore other Whitepapers:

Know More

Download Now

Please fill the Contact form below in order to view the white paper

Checked out our

API Linkedin
page yet?

Follow this page to explore how our offerings can accelerate your formulation success

Click here to visit